Name (Synonyms) | Correlation | |
---|---|---|
drug1519 | artus Influenza A/B RT-PCR Test Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003384 | Coxsackievirus Infections NIH | 1.00 |
D000257 | Adenoviridae Infections NIH | 0.71 |
D018184 | Paramyxoviridae Infections NIH | 0.58 |
D018357 | Respiratory Syncytial Virus Infections NIH | 0.50 |
D007251 | Influenza, Human NIH | 0.38 |
D014777 | Virus Diseases NIH | 0.13 |
D003141 | Communicable Diseases NIH | 0.10 |
D007239 | Infection NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: - the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment; - the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment; - the impact of plasma transfusion on the reduction of viral load and inflammation - safety and tolerability - clinical efficacy
Description: Semiquantitative measure of viral load by rtPCR for SARS-CoV-2 by nasopharyngeal swabs, at diagnosis and on day 1,3,7
Measure: Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs Time: Change from day of diagnosis at day 1Description: 7-point ordinal scale measure on day 0 (Baseline), day 1, 3 and 7 after plasma transfusion
Measure: Number of patients with improvement in the 7-points Ordinal Scale Time: At day 7Description: AE will be assessed by the DAIDS scale on day 1, 3, 7 and 21. Relatedness with plasma transfusion will also be reported.
Measure: Proportion of patients with adverse events, severity of adverse events Time: At day 21